News Conference News AHA 2022 IRONMAN Misses but Lends Support to IV Iron Repletion in HF Shelley Wood November 05, 2022
News Conference News AHA 2022 TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF Todd Neale November 05, 2022
News Conference News AHA 2022 Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions Yael L. Maxwell November 01, 2022
News Daily News STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF Shelley Wood October 17, 2022
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Daily News Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive Michael O'Riordan September 09, 2022
News Daily News Older Adults See Rebound in Rates of HF-Related Death: CDC Data Caitlin E. Cox September 09, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ESC 2022 Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR L.A. McKeown August 27, 2022
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Conference News ESC 2022 No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE Shelley Wood August 26, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2022 Todd Neale August 01, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for June 2022 Caitlin E. Cox July 04, 2022
News Daily News Quadruple Therapy Costs Prohibitive for Many HFrEF Patients L.A. McKeown June 21, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022